ARS Pharmaceuticals (SPRY) Operating Expenses (2020 - 2026)

ARS Pharmaceuticals has disclosed Operating Expenses across 7 years of filings, most recently posting $82.8 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $82.8 million, up 83.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $301.4 million (up 142.69% YoY), and the FY2025 annual result was $263.7 million, up 185.94% from the prior year.
• Operating Expenses came in at $82.8 million for Q1 2026 at ARS Pharmaceuticals, up from $69.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $85.7 million in Q3 2025 to a low of $6.8 million in Q2 2022.
• The 5-year median for Operating Expenses is $18.7 million (2023), against an average of $32.0 million.
• Across the five-year window, Operating Expenses tumbled 72.22% in 2022 and surged 299.82% in 2025, its largest moves.
• ARS Pharmaceuticals' Operating Expenses stood at $15.4 million in 2022, then slumped by 33.78% to $10.2 million in 2023, then surged by 285.14% to $39.4 million in 2024, then jumped by 76.6% to $69.6 million in 2025, then grew by 19.09% to $82.8 million in 2026.
• The last three Operating Expenses figures came in at $82.8 million (Q1 2026), $69.6 million (Q4 2025), and $85.7 million (Q3 2025), per Business Quant data.